Takeda Pharmaceutical

Latest Headlines

Latest Headlines

Japan's MHLW sanctions Takeda on Blopress marketing

Takeda Pharmaceutical was sanctioned by Japan's Ministry of Health, Labor and Welfare for using exaggerated marketing materials to promote hypertension medicine Blopress and was issued a business improvement order with which it will comply, according to a June 12 press release from the company.

Japan's Takeda breaks another trail in research pact with La Jolla's Sanford Consortium

Takeda Pharmaceutical has consolidated vaccine offices, signed a slew of alliances for discovery efforts and moved aggressively to refocus the company since Christophe Weber took over as CEO on April 1.

Takeda consolidates in U.S. amid sharp global vaccine competition

A move by Takeda Pharmaceutical to consolidate its Vaccine Business Unit into hubs should allow sharper focus on a complex set of vaccine programs covering norovirus, dengue and seasonal influenza in an increasingly competitive global horse race.

Leading Japan drug firms team up with AZ on parasitic disease research

Japan's Eisai, Shinogi and Takeda Pharmaceutical have teamed up with U.K.-based AstraZeneca on a broad R&D effort to find treatments for insect-borne parasitic diseases Chagas and leishmaniasis.

Contrave trial tussle brews between Takeda, Orexigen with Cleveland Clinic on the scene

A tussle over the termination of a trial to assess the cardiovascular safety of obesity drug Contrave is in swing, with Orexigen Therapeutics and Takeda Pharmaceutical entering a dispute process, according to Reuters, with earlier data breaches the subject of a separate issue.

Takeda, Orexigen end CV study for obesity drug Contrave

Takeda Development Center Americas, a unit of Japan's Takeda Pharmaceutical, and Orexigen Therapeutics have ended a cardiovascular outcomes trial that compared the obesity drug Contrave to a placebo in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors, the companies said.

Takeda joins with Japan's National Cancer Center on genomic screening

Takeda Pharmaceutical and Japan's National Cancer Center have entered into a plan to find and develop anticancer agents and a way to get them to Japanese patients quickly. The plan, in part, is to build on their collaboration on a genomic screening project led by the NCC.

Sumitomo Dainippon, Takeda call it quits on Latuda agreement in Europe

Sumitomo Dainippon Pharma and Takeda Pharmaceutical have canceled a four-year-old license and development agreement aimed at commercialization of lurasidone hydrochloride (Latuda) products following disappointing Phase III trials to treat schizophrenia announced last month.

Takeda financial hit from Actos settlement won't dim dividend

Takeda Pharmaceutical is about to make history that it would prefer not to make. When it produces its quarterly report for the fiscal year that ended March 31, it is expected to post its first net loss since it first listed on the Tokyo Stock Exchange in 1949.

BioXcel adds Takeda to its roster of A-list clients

BioXcel has added another big name to its list of clients. Takeda is the latest company to sign up to work with BioXcel, a database-driven drug discovery shop that already boasts relationships with Alexion, Sanofi, Teva and Vertex.